长风药业（02652）于2026年6月16日公告，基于董事会授权，公司于当日通过香港联合交易所场内回购6,500股H股股份，约占该公司现有已发行股本的0.0022%。回购价格介乎每股18.08港元至18.35港元，合计耗资约118,135港元（折合约11.81万港元）。
回购完成后，公司已发行股本由原先的300,833,086股降至300,826,586股，同时库藏股由1,390,500股增至1,397,000股，总股本仍为302,223,586股。该次回购依据2025年12月16日通过的授权进行，公司可回购的剩余额度为30,222,358股。截至公告日期，已于香港或其他证券交易所购回的股份累计1,397,000股，占授权通过日已发行股本约0.4622%。公司确认，此次股份购回已遵守上市规则及相关法律规定。
本公告由执行董事及联席公司秘书朱玉玉签署。该公司后续将在合规框架下继续执行相关股份事务。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.